MF
CRSP icon

Manchester Financial’s CRISPR Therapeutics CRSP Stock Holding History

Manchester Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-75
Closed -$9K – 200
2021
Q1 		$9K Hold
75
– – ﹤0.01% 442
2020
Q4 		$11K Hold
75
– – 0.01% 350
2020
Q3 		$6K Hold
75
– – ﹤0.01% 366
2020
Q2 		$6K Hold
75
– – ﹤0.01% 347
2020
Q1 		$3K Hold
75
– – ﹤0.01% 397
2019
Q4 		$5K Buy
+75
New +$4.09K ﹤0.01% 416
2019
Q3 		– Sell
-75
Closed -$4K – 132
2019
Q2 		$4K Buy
+75
New +$3K ﹤0.01% 399

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Manchester Financial's CRSP Position: Q2 2021 in Review

Manchester Financial sold out of CRISPR Therapeutics (CRSP) in Q2 2021, closing a stake of 75 shares — an estimated $9K sold.

Manchester Financial first reported a position in CRSP in Q2 2019 and held it in 7 quarters. The position peaked at $11K in Q4 2020. 498 funds tracked by Wall St. Rank hold CRSP as of Q2 2021.

  • Manchester Financial reported no remaining CRISPR Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Manchester Financial sold 75 CRISPR Therapeutics shares in Q2 2021, an estimated $9K.
  • Manchester Financial first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 7 quarters.
  • Manchester Financial's CRISPR Therapeutics position peaked at $11K in Q4 2020.
  • 498 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2021.

Based on Manchester Financial's 13F filing for Q2 2021, filed 21 Jul 2021.